942920-59-4

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-1-phenylsulfonyl-7-azaindole-2-carboxyaldehyde is used as a key intermediate for the synthesis of pharmaceuticals, particularly for the development of new drugs with potential therapeutic applications. Its unique structure and reactivity enable the creation of more complex chemical compounds that can be further modified and optimized for specific medical uses.
Used in Agrochemical Industry:
4-Bromo-1-phenylsulfonyl-7-azaindole-2-carboxyaldehyde is used as a building block for the synthesis of agrochemicals, such as pesticides and herbicides. Its reactivity allows for the development of innovative compounds that can be tailored to target specific pests or weeds, improving the effectiveness and selectivity of these products in agricultural settings.
Used in Organic Chemistry Research:
4-Bromo-1-phenylsulfonyl-7-azaindole-2-carboxyaldehyde is used as a valuable tool in the field of organic chemistry for the development of new and innovative compounds. Its unique structure and reactivity make it an ideal candidate for studying various chemical reactions and mechanisms, contributing to the advancement of knowledge and techniques in organic chemistry.

Upstream product

• 889939-25-7 1-(benzenesulfonyl)-4-bromo-1H-pyrrolo[2,3-b]pyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 109-94-4 formic acid ethyl ester 
• 348640-06-2 4-bromo-7-azaindole 
• 98-09-9 benzenesulfonyl chloride 

Downstream Products

• 942920-63-0 N-{[4-bromo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-methyl}-2-(methylsulfonyl)ethanamine 
• 942920-65-2 2-({[4-bromo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-methyl}amino)ethanol 
• 942920-64-1 {[4-bromo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-methyl}dimethylamine 
• 1089669-51-1 1,1-dimethylethyl 4-[({6-[2-(difluoromethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-3-pyridinyl}sulfonyl)amino]-1-piperidinecarboxylate 
• 1089669-82-8 C₂₄H₂₂F₂N₄O₆S₃ 
• 1089669-52-2 6-[2-(difluoromethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-3-pyridinesulfonamide 
• 1089669-66-8 5-[2-(difluoromethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-thiophenesulfonamide 
• 1089669-80-6 C₂₅H₂₄F₂N₄O₆S₃ 
• 1089669-81-7 C₂₅H₂₄F₂N₄O₆S₃ 
• 1089669-65-7 5-[2-(difluoromethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-N-(1,1-dioxidotetrahydro-3-thienyl)-2-thiophenesulfonamide 
• 1089669-64-6 N-(2-aminoethyl)-5-[2-(difluoromethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-2-thiophenesulfonamide 
• 1089669-63-5 2-(difluoromethyl)-4-[5-(1H-imidazol-1-ylsulfonyl)-2-thienyl]-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 1014613-65-0 1-(benzenesulfonyl)-4-bromo-2-(difluoromethyl)pyrrolo[2,3-b]pyridine 

Relevant academic research and scientific papers

HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE

This invention relates to compounds that are inhibitors of the CDK12 kinase. The compounds are useful in the treatment of disorders mediated by CDK12 kinase including myotonic dystrophy type 1 (DM1) and other disorders caused by the generation of RNA repeat expansion transcripts. In particular,the invention relates to compounds of the formula (I), or a pharmaceutically acceptable salts or N-oxides thereof, wherein R1a, R2, R3, R4a, R4b and R4c are as defined herein.

Azaquinazoline Inhibitors Of Atypical Protein Kinase C

The present application provides a compound of formula (I) and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disor

Discovery of GSK1070916, a potent and selective inhibitor of aurora B/C kinase

The Aurora kinases play critical roles in the regulation of mitosis and are frequently overexpressed or amplified in human tumors. Selective inhibitors may provide a new therapy for the treatment of tumors with Aurora kinase amplification. Herein we describe our lead optimization efforts within a 7-azaindole-based series culminating in the identification of GSK1070916 (17k). Key to the advancement of the series was the introduction of a 2-aryl group containing a basic amine onto the azaindole leading to significantly improved cellular activity. Compound 17k is a potent and selective ATP-competitive inhibitor of Aurora B and C with Ki* values of 0.38 ± 0.29 and 1.5 ± 0.4 nM, respectively, and is >250-fold selective over Aurora A. Biochemical characterization revealed that compound 17k has an extremely slow dissociation half-life from Aurora B (>480 min), distinguishing it from clinical compounds 1 and 2. In vitro treatment of A549 human lung cancer cells with compound 17k results in a potent antiproliferative effect (EC50 = 7 nM). Intraperitoneal administration of 17k in mice bearing human tumor xenografts leads to inhibition of histone H3 phosphorylation at serine 10 in human colon cancer (Colo205) and tumor regression in human leukemia (HL-60). Compound 17k is being progressed to human clinical trials.

NOVEL COMPOUNDS

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.

AZAINDOLE INHIBITORS OF AURORA KINASES

The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including s